Blueprint Medicines Corp — Form D
Blueprint Medicines Corp of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2014-11-20. The offering totals $50.0M, of which $50.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2014-11-20
- Form: D
- Accession: 0001597264-14-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $50.0M
- Investors: 29
- Date of first sale: 2014-11-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-228724
Issuer
- Name: Blueprint Medicines Corp
- CIK: 0001597264
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 215 FIRST STREET, CAMBRIDGE, MA, 02142
- Phone: 617-374-7580
Officers, directors & promoters (16)
| Name | Role | Location |
|---|
| Jeffrey W Albers | Director | Waltham, MA |
| Alexis S Borisy | Director | Cambridge, MA |
| Stephen S Knight | Director | Cambridge, MA |
| Nicholas S Lydon | Director | Cambridge, MA |
| Daniel S Lynch | Director | Cambridge, MA |
| David S Schenkein | Director | Cambridge, MA |
| Thilo S Schroeder | Director | Cambridge, MA |
| Jeffrey W Albers | Executive Officer | Waltham, MA |
| Christine W Bellon | Executive Officer | Cambridge, MA |
| Kyle W Kuvalanka | Executive Officer | Cambridge, MA |
| Christoph S Lengauer | Executive Officer | Cambridge, MA |
| Alexis Borisy | Director | Boston, MA |
| Alexis Borisy | Executive Officer | Boston, MA |
| Kyle Kuvalanka | Executive Officer | Dartmouth, A5 |
| Nick S Lydon | Director | Cambridge, MA |
| Christine Bellon | Executive Officer | Cambridge, MA |
Other filings by this issuer (1)
More